Drug Trial Radar · NCT00106431
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Jan 1, 2005
Primary completion
Jun 1, 2008
Study completion Dec 1, 2008
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Celgene Corporation
- First posted
- Mar 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted at approximately 30 sites, primarily in the United States, Europe and Russia. It assessed the efficacy, safety, and tolerability of romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL). Study patients (pts) received romidepsin in a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although pts who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
Conditions
- Cutaneous T-cell Lymphoma
Interventions
romidepsin (depsipeptide, FK228)Drug
Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percent of Patients (Pts) With Objective Disease ResponseTime frame: 6 months
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
UCLA Jonsson Cancer Center
Los Angeles, California
Stanford Comprehensive Cancer Center
Stanford, California
Boston Medical Center
Boston, Massachusetts
University of Pennsylvania Abrahamson Cancer Center
Philadelphia, Pennsylvania
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Research Site
Multiple Locations, France
Research Site
Multiple Locations, Germany
Research Site
Multiple Locations, Poland
Research Site
Multiple Locations, Russia
Research Site
Multiple Locations, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.